OCX: OncoCyte Corp.
About
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.
Current Value
$2.501 Year Return
Current Value
$2.501 Year Return
Key Details
Market Cap
$42.93M
P/E Ratio
-0.58
1Y Stock Return
-36.09%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
3.5
Strategies that include OCX
Stock's related to OCX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NOMD | 28.19% | $2.74B | +4.53% | 2.67% |
| FLUX | 24.98% | $37.37M | -36.18% | 0.00% |
| SPTN | 24.43% | $615.01M | -17.44% | 4.80% |
| WMK | 23.75% | $1.88B | +14.23% | 1.95% |
| SEG | 23.01% | $319.72M | +12.41% | 0.00% |
| TXMD | 21.54% | $14.99M | -53.32% | 0.00% |
| BRK.B | 21.03% | $1.01T | +29.88% | 0.00% |
| MNOV | 20.89% | $93.19M | +2.15% | 0.00% |
| INN | 20.63% | $661.35M | -1.61% | 4.92% |
| YRD | 20.60% | $518.01M | +101.02% | 3.44% |
| IMKTA | 20.38% | $1.30B | -13.30% | 0.96% |
| MAC | 20.12% | $4.42B | +78.32% | 3.51% |
| ONIT | 19.82% | $240.15M | +14.44% | 0.00% |
| EPD | 19.42% | $68.56B | +19.13% | 6.56% |
| RDNT | 19.26% | $5.91B | +151.89% | 0.00% |
| APT | 19.26% | $58.84M | +13.35% | 0.00% |
| MRNA | 18.97% | $14.35B | -51.66% | 0.00% |
| DIS | 18.85% | $203.59B | +19.03% | 0.40% |
| CYRX | 18.83% | $342.80M | -48.82% | 0.00% |
| CUBE | 18.78% | $11.08B | +25.82% | 4.18% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AVGO | -<0.01% | $772.28B | +68.52% | 9.87% |
| SFIX | -0.01% | $480.74M | +11.14% | 0.00% |
| ALT | 0.01% | $531.30M | +194.09% | 0.00% |
| ROK | 0.01% | $31.40B | +3.25% | 1.80% |
| TCTM | -0.01% | $8.10M | -42.99% | 0.00% |
| EGBN | -0.02% | $861.65M | +20.89% | 5.30% |
| VECO | -0.02% | $1.48B | -9.94% | 0.00% |
| QNRX | -0.02% | $3.20M | -85.07% | 0.00% |
| LAD | -0.02% | $9.87B | +38.08% | 0.56% |
| SMLR | -0.02% | $336.72M | +25.48% | 0.00% |
| WST | 0.02% | $22.02B | -13.73% | 0.27% |
| CLBK | 0.03% | $1.89B | +4.93% | 0.00% |
| IVT | -0.03% | $2.38B | +27.45% | 2.91% |
| GCI | -0.04% | $731.16M | +146.77% | 0.00% |
| CDRE | -0.04% | $1.30B | +1.85% | 1.10% |
| TOST | -0.04% | $24.14B | +207.53% | 0.00% |
| JILL | 0.04% | $368.36M | -21.45% | 0.58% |
| OMF | -0.04% | $6.51B | +43.89% | 7.52% |
| CGNT | 0.04% | $501.83M | +59.73% | 0.00% |
| MELI | -0.04% | $97.16B | +28.15% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MBI | -32.36% | $335.78M | +105.79% | 0.00% |
| YY | -23.82% | $1.47B | -12.63% | 0.00% |
| CORT | -21.54% | $5.69B | +113.63% | 0.00% |
| MTLS | -17.75% | $399.00M | +3.76% | 0.00% |
| ALTR | -16.63% | $8.88B | +43.93% | 0.00% |
| SUN | -15.95% | $7.32B | +1.51% | 6.47% |
| VIRC | -15.72% | $253.30M | +129.35% | 0.53% |
| CCL | -14.81% | $31.85B | +76.97% | 0.00% |
| REFI | -14.70% | $311.99M | +6.37% | 11.85% |
| NYMT | -14.56% | $538.04M | -30.85% | 13.54% |
| ANSS | -14.51% | $29.69B | +13.34% | 0.00% |
| BIRK | -14.41% | $8.75B | +7.40% | 0.00% |
| AVXL | -13.73% | $698.71M | +22.62% | 0.00% |
| BDX | -13.63% | $64.35B | -5.72% | 1.71% |
| HUSA | -13.45% | $16.69M | -11.56% | 0.00% |
| RCL | -13.39% | $63.10B | +123.86% | 0.17% |
| CUK | -13.35% | $3.29B | +77.76% | 0.00% |
| CAVA | -13.17% | $16.15B | +322.78% | 0.00% |
| LAUR | -12.96% | $2.83B | +41.77% | 0.00% |
| TTWO | -12.85% | $32.67B | +19.44% | 0.00% |
ETF's related to OCX
News
Yahoo
OncoCyte Corp (OCX) advances in global transplant testing while navigating pre-revenue challenges and competitive market dynamics.
Yahoo
Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phaseFDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today published the following letter to shareholders in conjunction with its third quart
SeekingAlpha
OncoCyte Corporation (NASDAQ:OCX) Q3 2024 Results Conference Call November 12, 2024 5:00 PM ETCompany ParticipantsJulie Silber - PCG AdvisoryJosh Riggs -...
Yahoo
Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ETIRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its
Yahoo
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles. Oncocyte management will also be available for one-on-one meetings with investors. To schedule a one-on-one meeting, please contact Julie Silber at PCG Advisory (jsilber@pcgadvisory.com) or request a meeting via the LD Micro Conferenc
Yahoo
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test, DetermaIO™.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.